HomeAI · summaries
Storia in 6 fonti
So Far, So Good for PCSK9-Targeting Gene Therapy in Hypercholesterolemia
Tweaked lipid nanoparticle delivery system showed early safety
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting…
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for…
- ·
endpoints.news
Lilly reports new data on PCSK9 base editing gene therapy from Verve buyout
Eli Lilly said a base editing gene therapy from its purchase of Verve Therapeutics delivered additional positive results in a Phase 1b trial, paving the way for a mid-stage test…
- ·
spectator.com
Gene-editing drugs are opening a new frontier in medicine
Medicines that we take only a few times and which permanently alter the trajectory of our lives for the better, are on the way.
- ·
medpagetoday.com
So Far, So Good for PCSK9-Targeting Gene Therapy in Hypercholesterolemia
Tweaked lipid nanoparticle delivery system showed early safety
- ·
arstechnica.com
Bad cholesterol slashed 62% by single dose of gene-editing drug in small trial
The interim Phase I trial data was only from 35 people, but results look good so far.
- ·
One dose of gene-editing drug cut bad cholesterol 62% for months in small trial
The interim Phase I trial data was only from 35 people, but results look good so far.
- ·
healio.com
PCSK9 inhibition via base editing lowers LDL in patients with genetic high cholesterol
Genetic PCSK9 inhibition via base editing appeared safe and demonstrated dose-dependent, durable reductions in PCSK9 and LDL cholesterol, researchers reported.At the highest dose,…